Clinical Trial Update: First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Genmab-sponsored first-in-human trial in relapsed/refractory B-cell lymphomas spans Phase 1/2 and is currently active/not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• High-grade B-cell Lymphoma
• Indolent B-cell Non-hodgkin Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Mediastinal Large B-cell Lymphoma
• Small Lymphocytic Lymphoma

Snippet

Sponsor: Genmab | Conditions: DLBCL, High-grade B-cell Lymphoma (HGBCL) | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING